公开(公告)号：US11524077B2

公开(公告)日：2022-12-13

申请号：US16878325

申请日：2020-05-19

申请人： Vascular BioSciences

发明人： David Mann

IPC分类号： A61K47/42 ,  A61K47/62 ,  A61K45/06 ,  C07K7/06 ,  A61K9/00 ,  A61K31/506 ,  A61K31/519 ,  A61K38/00

摘要： Disclosed are compositions and methods useful for oral delivery of targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to affect a beneficial therapeutic result. The disclosed targeting is useful for oral delivery of therapeutic and detectable agents to diseased tissue in an animal.

公开(公告)号：US11524072B2

公开(公告)日：2022-12-13

申请号：US17061696

申请日：2020-10-02

申请人： UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

发明人： Donald A. Harn ,  Rafaella Queiroz ,  Lisa Shollenberger ,  Emily-Joy Farah Samli

IPC分类号： A61K39/39 ,  A61K39/00 ,  A61K39/104 ,  A61K39/12 ,  A61K9/00 ,  A61K9/06 ,  A61K39/02 ,  A61K39/145 ,  A61K39/29 ,  A61K47/42 ,  A61K39/012 ,  A61K39/108 ,  A61K39/112 ,  A61K39/04 ,  A61K39/05 ,  A61K39/08 ,  A61K39/085 ,  A61K39/09 ,  A61K39/102 ,  A61K39/15 ,  A61K39/155 ,  A61K39/17 ,  A61K39/215 ,  A61K39/255 ,  A61K39/265

摘要： A vaccine delivery method is presented that includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also included are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions.

公开(公告)号：US20220370573A1

公开(公告)日：2022-11-24

申请号：US17541546

申请日：2021-12-03

申请人： Allergan, Inc.

发明人： Ahmet Tezel ,  Wendy M. Blanda ,  Patrick M. Hughes ,  Scott M. Whitcup ,  James N. Chang ,  Michael R. Robinson

IPC分类号： A61K38/48 ,  A61K47/36 ,  A61L27/20 ,  A61L27/54 ,  A61K8/64 ,  C12N9/64 ,  A61K8/66 ,  A61K8/73 ,  A61Q19/08 ,  A61K47/32 ,  A61K47/38 ,  A61K47/42

摘要： Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.

公开(公告)号：US20220362205A1

公开(公告)日：2022-11-17

申请号：US17873800

申请日：2022-07-26

申请人： Zhuhai Beihai Biotech Co., Ltd.

发明人： Qun Sun

IPC分类号： A61K31/337 ,  A61K47/64 ,  A61K9/08 ,  A61K47/42

摘要： This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

公开(公告)号：US20220354790A1

公开(公告)日：2022-11-10

申请号：US17621587

申请日：2020-06-11

申请人： KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION

发明人： Kwang Dae HONG ,  Jihun SEO ,  Joon Bum LEE

IPC分类号： A61K9/16 ,  A61K9/50 ,  A61K47/42 ,  A61K47/36 ,  A61K9/00

摘要： The present invention relates to an in-vivo bulking agent which can be used as a medicinal agent for prevention or treatment of at least one disease selected from the group consisting of urinary incontinence, fecal incontinence, and gastroesophageal reflux or as a filler for use in a plastic surgery procedure, and to a preparation method therefor. The in-vivo bulking agent can exhibit a bulking effect when injected into the body and particularly, is highly biocompatible because a first composition in which silicone particles are coated with a zwitterionic polymer having a surfactant property is introduced into a second composition, whereby the bulking agent can inhibit inflammatory reactions in vivo.

公开(公告)号：US11491216B2

公开(公告)日：2022-11-08

申请号：US16645048

申请日：2018-09-04

申请人： Merck Sharp & Dohme Corp. ,  Richard J. Porambo ,  Chitrananda Abeygunawardana ,  Luwy Kavuka Musey ,  Michael J. Kosinski ,  Yadong Adam Cui ,  Julie Marie Skinner

发明人： Richard J. Porambo ,  Chitrananda Abeygunawardana ,  Luwy Kavuka Musey ,  Michael J. Kosinski ,  Yadong Adam Cui ,  Julie Marie Skinner

IPC分类号： A61K39/09 ,  A61K39/39 ,  A61K47/42

摘要： The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.

公开(公告)号：US11484595B2

公开(公告)日：2022-11-01

申请号：US15841059

申请日：2017-12-13

申请人： JYSK Skin Solutions PTE .LTD.

发明人： Siak-Khim Tan ,  Janifer Yeo-Tan

IPC分类号： A61K38/10 ,  A61K38/16 ,  A61K38/00 ,  C07K14/575 ,  A61P23/00 ,  A61P17/00 ,  A61P29/00 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  A61K39/02 ,  A61K39/08 ,  A61K9/127 ,  A61K47/42 ,  A61K31/60 ,  A61K38/48 ,  A61K9/00 ,  A61K9/107 ,  A61K38/08 ,  C07K14/33 ,  C07K7/08 ,  A61P25/00 ,  A61K39/00

摘要： A carrier molecule composition. Specific implementations may include: a carrier molecule including at least one cell penetrating peptide (CPP) where the carrier molecule may include at least one hydrophobic domain and where the carrier is non-covalently associated with a biologically active molecule in one of a micelle and a liposome.

公开(公告)号：US20220305089A1

公开(公告)日：2022-09-29

申请号：US17633836

申请日：2020-08-14

申请人： OCTAPHARMA AG

发明人： Ronny SCHMIDT ,  Tilo SCHWIENTEK

IPC分类号： A61K38/37 ,  A61K47/02 ,  A61K47/18 ,  A61K47/26 ,  A61K47/42 ,  A61K9/19 ,  A61K9/08

摘要： The invention relates to a pharmaceutical composition comprising an isolated Factor VIII protein and/or an isolated VWF protein in a stabilizing buffer composition, wherein said pharmaceutical composition is free of albumin and said stabilizing buffer 5 composition comprises cryoprotectants and bulking agents in a weight ratio of more than 0.65:1. The invention relates further relates to the use of a stabilizing buffer formulating an FVIII protein and/or a VWF protein to the use of a VWF protein for stabilizing a FVIII protein in vitro.

公开(公告)号：US20220305013A1

公开(公告)日：2022-09-29

申请号：US17619837

申请日：2020-06-18

申请人： THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Molly S. SHOICHET ,  Ahil N. GANESH ,  Eric N. DONDERS ,  Brian K. SHOICHET ,  Hayarpi TOROSYAN

IPC分类号： A61K31/506 ,  A61K9/10 ,  A61K47/42 ,  A61K31/4174 ,  A61K31/438 ,  A61K47/28 ,  A61K47/34 ,  A61K31/566 ,  A61K31/44

摘要： The present application provides a colloid drug aggregate composition and methods of use and manufacture thereof. While the formation of colloidal aggregates leads to artifacts in early drug discovery, their composition makes them attractive as nanoparticle formulations for targeted drug delivery. The present application provides an acid-responsive composition comprising: a colloidal aggregate of one or more drugs and a stabilizing agent, wherein the colloidal aggregate disrupts, dissolves or disassembles when the acid-responsive composition is in an acid environment having a pH of less than 7.4. The colloidal aggregate of the composition will disassemble upon contact with acid or upon introduction to an acidic environment, such as is found in the endosomes of cells. This approach makes this composition an attractive vehicle for drug delivery to a target site in a subject or to cells.

公开(公告)号：US11452688B2

公开(公告)日：2022-09-27

申请号：US16554015

申请日：2019-08-28

申请人： KYUSHU UNIVERSITY ,  NISSAN CHEMICAL INDUSTRIES, LTD.

发明人： Masahiro Goto ,  Nobuhide Miyachi ,  Takehisa Iwama ,  Takayuki Imoto

IPC分类号： A61K9/00 ,  A61K47/10 ,  A61K47/12 ,  A61K47/42 ,  A61K47/18 ,  A61K47/26 ,  A61Q19/00 ,  A61K9/06 ,  A61K38/28 ,  A61K31/728 ,  A61K8/02 ,  A61K8/34 ,  A61K8/36 ,  A61K8/60 ,  A61K8/64

摘要： A transdermally absorbable base material including: a lipid peptide compound including at least one of compound of Formula (1) below and the similar compounds or pharmaceutically usable salts thereof; a surfactant; a specific polyhydric alcohol; a fatty acid; and water, wherein R1 is a C9-23 aliphatic group; R2 is a hydrogen atom or a C1-4 alkyl group that optionally has a branched chain having a carbon atom number of 1 or 2; R3 is a —(CH2)n—X group; n is a number of 1 to 4; and X is amino group, guanidino group, —CONH2 group, or a 5-membered cyclic group optionally having 1 to 3 nitrogen atoms, a 6-membered cyclic group optionally having 1 to 3 nitrogen atoms, or a condensed heterocyclic group constituted by a 5-membered cyclic group and a 6-membered cyclic group which optionally have 1 to 3 nitrogen atoms.